Vebreltinib · APL-101, PLB-1001

What is Vebreltinib?

Vebreltinib is an orally bioavailable small molecule that selectively binds the c-Met receptor tyrosine kinase, inhibiting its phosphorylation and downstream signaling. It is being studied in solid tumors, including non-small cell lung, gastric, renal, and glioblastoma cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

APL-101, PLB-1001, CBI-3103, CBT-101, Bozitinib

Drug type

Small molecule

Targets

c-Met (hepatocyte growth factor receptor) (MET)

Mechanism

Inhibitor of c-Met (hepatocyte growth factor receptor) (MET)

Pathways

c-Met signal transduction, tumor cell proliferation, tumor cell survival, tumor invasion and metastasis, tumor angiogenesis

Therapy area

Oncology

Developer

Apollomics Inc. (APLM)

FDA status

Investigational, not approved in the US. Most advanced trial: Phase 1/2

UNII

2WZP8A9VFN

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced CancerBrain TumorColon CancerEGFR Gene MutationGastric CancerGastroesophageal Junction AdenocarcinomaGlioblastoma MultiformeHGFLung CancerMET AmplificationNSCLCPancreatic CancerRenal CancerSolid Tumors

Other drugs acting on MET

More from Apollomics

Sources

• NCI Thesaurus
• ClinicalTrials.gov NCT03175224
• ClinicalTrials.gov NCT05367388
• ClinicalTrials.gov NCT05367388

Updated Oct 11, 2026. Something wrong or missing? Report it on the APLM page.